scholarly journals 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches

2019 ◽  
Vol 12 ◽  
pp. 175628481983620 ◽  
Author(s):  
Arno Kornberg ◽  
Helmut Friess
Keyword(s):  
Positron Emission Tomography ◽  
Therapeutic Strategy ◽  
Nuclear Imaging ◽  
Tumor Burden ◽  
Emission Tomography ◽  
Individual Treatment ◽  
Imaging Device ◽  
Tumor Invasiveness ◽  
Positron Emission ◽  
The Individual

Hepatocellular carcinoma (HCC) is a global health issue with increasing incidence and high mortality rate. Depending on the tumor load and extent of underlying liver cirrhosis, aggressive surgical treatment by hepatectomy or liver transplantation (LT) may lead to cure, whereas different modalities of liver-directed locoregional or systemic tumor treatments are currently available for a noncurative approach. Apart from tumor burden and grade of liver dysfunction, assessment of prognostic relevant biological tumor aggressiveness is vitally important for establishing a promising multimodal therapeutic strategy and improving the individual treatment-related risk/benefit ratio. In recent years, an increasing body of clinical evidence has been presented that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET), which is a standard nuclear imaging device in oncology, may serve as a powerful surrogate for tumor invasiveness and prognosis in HCC patients and, thereby, impact individual decision making on most appropriate therapy concept. This review describes the currently available data on the prognostic value of 18F-FDG PET in patients with early and advanced HCC stages and the resulting implications for treatment strategy.

scholarly journals 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Miao Chen ◽  
Wenjia Zhu ◽  
Jianhua Du ◽  
Chen Yang ◽  
Bing Han ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Disease Progression ◽  
Fdg Pet ◽  
Tumor Burden ◽  
Emission Tomography ◽  
Focal Lesions ◽  
Bone Marrow Uptake ◽  
Positron Emission

AbstractThe optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the assessment of tumor burden in NDMM. This study evaluated 64 NDMM patients between February 2015 and July 2018. AC-PET and FDG-PET were used to assess myeloma lesions. The clinical data, imaging results, and their correlations were analyzed. Diffuse bone marrow uptake in AC-PET was significantly correlated with biomarkers for tumor burden, including serum hemoglobin (P = 0.020), M protein (P = 0.054), the percentage of bone marrow plasma cells (P < 0.001), and the Durie–Salmon stage of the disease (P = 0.007). The maximum standard uptake value (SUVmax) of focal lesions and high diffuse bone marrow uptake in AC-PET showed stronger correlations with high-risk disease (P = 0.017, P = 0.013) than those in FDG-PET. Moreover, the presence of diffuse bone marrow uptake, more than ten focal lesions, and an SUVmax of focal lesions of > 6.0 in AC-PET, but not in FDG-PET, predicted a higher probability of disease progression and shorter progression-free survival (P < 0.05). AC-PET outperformed FDG-PET in tumor burden evaluation and disease progression prediction in NDMM.

scholarly journals Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Han Feng ◽  
Xiaobo Wang ◽  
Jian Chen ◽  
Jing Cui ◽  
Tang Gao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Tumor Imaging ◽  
Single Photon ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Emission Tomography ◽  
Metabolic Imaging ◽  
Emission Computed Tomography ◽  
Positron Emission

Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[18F]fluoro-glucose (18F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for this purpose. The powerful impact of 18F-FDG has prompted intensive research efforts into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99mTc, 111In, 18F, 68Ga, and 64Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies. Moreover, 99mTc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18F-FDG. In this review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will be summarized.

Radiometals: towards a new success story in nuclear imaging?

2015 ◽  
Vol 44 (11) ◽  
pp. 4845-4858 ◽  
Author(s):  
David Brasse ◽  
Aline Nonat
Keyword(s):  
Positron Emission Tomography ◽  
Nuclear Imaging ◽  
Emission Tomography ◽  
Success Story ◽  
Positron Emission

The use of radiometal isotopes in positron emission tomography: a new success story in nuclear imaging?

The Application of Positron Emission Tomography to the Study of Mass Transfer in Fractured Rocks

1990 ◽  
Vol 212 ◽  
Author(s):  
D. Gilling ◽  
N. L. Jefferies ◽  
P. Fowles ◽  
M. R. Hawkesworth ◽  
D. J. Parker
Keyword(s):  
Positron Emission Tomography ◽  
Mass Transfer ◽  
Hydraulic Properties ◽  
Fractured Rock ◽  
Fracture Network ◽  
Emission Tomography ◽  
Single Fracture ◽  
Hard Rocks ◽  
Positron Emission ◽  
The Individual

ABSTRACTWater flow in hard rocks takes place dominantly in fractures. In order to predict the transport of dissolved radioelements through a fractured rock it is necessary to take into account both the geometry of the fracture network and the hydraulic properties of the individual fractures. This paper describes a technique for studying mass transfer in a single fracture. The technique is positron emission tomography (PET) and it offers the potential for visualising quantitatively the migration of dissolved tracers. Preliminary experiments have been undertaken involving the flow of Na-22 and F-18 labelled solutions through artificial fractures. The results demonstrate that PET is well suited to this application.

Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS

2012 ◽  
Vol 30 (35) ◽  
pp. 4317-4322 ◽  
Author(s):  
Jehan Dupuis ◽  
Alina Berriolo-Riedinger ◽  
Anne Julian ◽  
Pauline Brice ◽  
Christelle Tychyj-Pinel ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Prospective Study ◽  
Tumor Burden ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Interim Pet ◽  
Positron Emission ◽  
End Of Treatment ◽  
A Prospective Study ◽  
Fluorodeoxyglucose Positron Emission

Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with aggressive lymphoma, but less is known about the utility of PET in patients with follicular lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negative in 78%. With a median follow-up of 23 months, 2-year progression-free survival rates were 86% for interim PET–negative versus 61% for interim PET–positive patients (P = .0046) and 87% for final PET–negative versus 51% for final PET–positive patients (P < .001), respectively. Two-year overall survival also significantly differed according to final PET results: 100% versus 88% (P = .0128). Conclusion PET performed either after four cycles of R-CHOP or at the end of therapy was strongly predictive of outcome in this prospective study. Therapeutic intervention based on PET results during or after inductive treatment should be evaluated.

scholarly journals The utilization of positron emission tomography in the evaluation of renal health and disease

2021 ◽  
Author(s):  
Kwame Anokye Amoabeng ◽  
Sanna Laurila ◽  
Luis Eduardo Juárez-Orozco ◽  
Anne Beate Langeland Marthinsen ◽  
Dariusz Moczulski ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Nuclear Imaging ◽  
Fatty Acid Uptake ◽  
Renal Perfusion ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Acid Uptake ◽  
Renal Metabolism ◽  
Positron Emission

Abstract Purpose Positron emission tomography (PET) is a nuclear imaging technique that uses radiotracers to visualize metabolic processes of interest across different organs, to diagnose and manage diseases, and monitor therapeutic response. This systematic review aimed to characterize the value of PET for the assessment of renal metabolism and function in subjects with non-oncological metabolic disorders. Methods This review was conducted and reported in accordance with the PRISMA statement. Research articles reporting “kidney” or “renal” metabolism evaluated with PET imaging between 1980 and 2021 were systematically searched in Medline/PubMed, Science Direct, and the Cochrane Library. Search results were exported and stored in RefWorks, the duplicates were removed, and eligible studies were identified, evaluated, and summarized. Results Thirty reports met the inclusion criteria. The majority of the studies were prospective (73.33%, n = 22) in nature. The most utilized PET radiotracers were 15O-labeled radio water (H215O, n = 14) and 18F-fluorodeoxyglucose (18F-FDG, n = 8). Other radiotracers used in at least one study were 14(R,S)-(18)F-fluoro-6-thia-heptadecanoic acid (18F-FTHA), 18F-Sodium Fluoride (18F-NaF), 11C-acetate, 68-Gallium (68Ga), 13N-ammonia (13N-NH3), Rubidium-82 (82Rb), radiolabeled cationic ferritin (RadioCF), 11C‐para-aminobenzoic acid (11C-PABA), Gallium-68 pentixafor (68Ga-Pentixafor), 2-deoxy-2-F-fluoro-d-sorbitol (F-FDS) and 55Co-ethylene diamine tetra acetic acid (55Co-EDTA). Conclusion PET imaging provides an effective modality for evaluating a range of metabolic functions including glucose and fatty acid uptake, oxygen consumption and renal perfusion. Multiple positron emitting radiolabeled racers can be used for renal imaging in clinical settings. PET imaging thus holds the potential to improve the diagnosis of renal disorders, and to monitor disease progression and treatment response.

Sign in / Sign up

Export Citation Format

Share Document